Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene is a research paper published in Molecular Therapy — Methods & Clinical Development (2022). On theSindex it has a DataRank of 0.701. It has been cited 22 times, with 19 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.231
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 19 citers.
National Cancer Institute
Grant: P30CA 15083
National Cancer Institute
Grant: P50CA 116201
National Cancer Institute
Grant: R01CA 200507
National Institutes of Health
Grant: 3P30CA015083-37S2
Mayo Comprehensive Cancer Center Grant
National Institutes of Health
Grant: 5R01CA200507-04
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers
National Institutes of Health
Grant: 5P50CA116201-08
Career Development (Ingle)
Fields of Study
Keywords
Sustainable Development Goals